Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about tepotinib
Marketing authorisation indication
2.1 Tepotinib (Tepmetko, Merck) is indicated for 'the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in tepotinib's summary of product characteristics.
Price
2.3 The list price of tepotinib is confidential.
The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation